NASDAQ: PRQRProqr Therapeutics Nv Stock
$1.94-0.02 (-1.02%)
Updated Apr 26, 2024
PRQR Price
$1.94
Fair Value Price
-$0.54
Market Cap
$157.83M
52 Week Low
$1.11
52 Week High
$3.29
P/E
-5.11x
P/B
3.51x
P/S
15.16x
PEG
N/A
Dividend Yield
N/A
Revenue
$10.35M
Earnings
-$31.24M
Gross Margin
100%
Operating Margin
-280.72%
Profit Margin
-295.2%
Debt to Equity
2.33
Operating Cash Flow
$24M
Beta
0.91
Next Earnings
May 22, 2024
Ex-Dividend
N/A
Next Dividend
N/A
PRQR Overview
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PRQR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PRQR ($1.94) is overvalued by 461.66% relative to our estimate of its Fair Value price of -$0.54 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PRQR ($1.94) is not significantly undervalued (461.66%) relative to our estimate of its Fair Value price of -$0.54 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PRQR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PRQR due diligence checks available for Premium users.
Be the first to know about important PRQR news, forecast changes, insider trades & much more!
PRQR News
Valuation
PRQR fair value
Fair Value of PRQR stock based on Discounted Cash Flow (DCF)
Price
$1.94
Fair Value
-$0.54
Undervalued by
461.66%
PRQR ($1.94) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PRQR ($1.94) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PRQR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PRQR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.11x
Industry
14.88x
Market
41.14x
PRQR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.51x
Industry
5.85x
PRQR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PRQR's financial health
Profit margin
Revenue
$6.9M
Net Income
-$6.1M
Profit Margin
-88.2%
PRQR's Earnings (EBIT) of -$29.06M... subscribe to Premium to read more.
Interest Coverage Financials
PRQR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$153.2M
Liabilities
$107.2M
Debt to equity
2.33
PRQR's short-term assets ($131.51M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PRQR's short-term assets ($131.51M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PRQR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PRQR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.0M
Investing
$5.6M
Financing
-$1.2M
PRQR's operating cash flow ($23.42M)... subscribe to Premium to read more.
Debt Coverage Financials
PRQR vs Biotech Stocks
Proqr Therapeutics Nv Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.